EXCLUSIVE LICENSE AGREEMENT. Upon notice received by the Laboratory from the Cooperator that it wishes to exercise the option referred to in paragraph 5.10.1 above, the terms of the exclusive license will be negotiated promptly by the Laboratory and the Cooperator. Any exclusive license will be subject to the reservation by the Government of a non-exclusive, irrevocable, paid-up license to practice or have practiced on its behalf the Subject Invention throughout the world.
EXCLUSIVE LICENSE AGREEMENT. THIS EXCLUSIVE LICENSE AGREEMENT AND THE ATTACHED APPENDICES A, B, AND C (collectively, the “Agreement”) is made and is effective this 1st day of June, 2014 (the “Effective Date”), by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (“The Regents”), a California corporation having its corporate offices located at 0000 Xxxxxxxx Xxxxxx, Xxxxxxx, Xxxxxxxxxx 00000-0000, acting through The Office of Intellectual Property and Industry Sponsored Research of the University of California, Los Angeles, located at 00000 Xxxxxxx Xxxxxx, Xxxxx 000, Xxx Xxxxxxx, XX, 00000-0000, and FIBROCELL SCIENCE, INC. (“Licensee”), a Delaware corporation having a principal place of business at 000 Xxxxxxxxx Xxxx., Xxxxx, XX, 00000. This Agreement refers to The Regents and Licensee collectively as the “Parties” and individually as a “Party.”
EXCLUSIVE LICENSE AGREEMENT. This Agreement is made effective the 15th day of October, 2007, by and between Marshfield Clinic (hereinafter called “MARSHFIELD CLINIC”), a nonstock, nonprofit Wisconsin corporation, and Osmetech Molecular Diagnostics (hereinafter called “Licensee”), a corporation organized and existing under the laws of Delaware;
EXCLUSIVE LICENSE AGREEMENT. The OPC Foundation, a non-‐profit corporation (the "OPC Foundation"), has established a set of specifications intended to xxxxxx greater interoperability between automation/control applications, field systems/devices, and business/office applications in the process control industry.
EXCLUSIVE LICENSE AGREEMENT. This Exclusive License Agreement (the “Agreement”) is made and entered into as of July 2, 2007 (the “Effective Date”) by and between CHILDREN’S MEDICAL CENTER CORPORATION, a charitable corporation duly organized and existing under the laws of the Commonwealth of Massachusetts and having its principal office at 000 Xxxxxxxx Xxxxxx, Xxxxxx, Xxxxxxxxxxxxx, 00000, X.X.X. (hereinafter referred to as “CMCC”), and InVivo Therapeutics Corporation, a business corporation organized and existing under the laws of the State of Delaware and having its principal office at 0 Xxxx Xxxxxxxxxx Xxxxx, Xxxxxxxxx, XX (hereinafter referred to as “Licensee”).
EXCLUSIVE LICENSE AGREEMENT. 56 SECTION 5.18. DEVELOPMENTAL PRODUCTS........................................56 SECTION 5.19. NONCOMPETITION AGREEMENTS.....................................57 SECTION 5.20. WAIVER OF RIGHT OF FIRST REFUSAL..............................57 SECTION 5.21. IGF'S CONTINUED ACCESS TO KEY EMPLOYEES.......................58 ARTICLE VI CONDITIONS PRECEDENT TO THE OBLIGATIONS OF THE PURCHASER
EXCLUSIVE LICENSE AGREEMENT. On or before the Closing Date, Sellers and Purchaser shall enter into the License Agreement in substantially the form set forth in Exhibit G.
EXCLUSIVE LICENSE AGREEMENT. F. The license granted hereunder shall not be construed to confer any rights upon Licensee by implication, estoppel or otherwise as to any inventions, discoveries, know-how, technology or other intellectual property not described in Paragraph A of this Article II. As a condition of the license granted hereunder, Licensee hereby irrevocably covenants and agrees that it will not, directly or indirectly, in any respect, use non-public information it has acquired in the course of prosecution of the Patent Rights from CMCC and/or patent counsel of CMCC prosecuting the Patent Rights, or recommendations made by Licensee that have been implemented, in whole or in part, with respect to prosecution of the Patent Rights, as a part of a Challenge (as defined below) to the Patent Rights or CMCC’s ownership of such rights. Any assignment or sublicense granted by Licensee shall contain an identical commitment by the assignee or sublicensee.
EXCLUSIVE LICENSE AGREEMENT. To induce the LICENSEE to deliver the above-specified Common Stock to the BOARD, BOARD hereby represents and warrants to the LICENSEE as follows:
EXCLUSIVE LICENSE AGREEMENT. THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made and entered into as of the 28th day of September, 2007 (the “Effective Date”) by and between Dicerna Pharmaceuticals, Inc., a Delaware corporation with a principal place of business at 00 Xxxxxxxx Xxxxxx, Sudbury, MA 01776 (“Dicerna”) and City of Hope, a California nonprofit public benefit corporation located at 0000 Xxxx Xxxxxx Xxxx, Duarte, California 91010 (“COH”). Dicerna and COH are each sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
